The radiotoxicity of 131I therapy of thyroid cancer:: Assessment by micronucleus assay of B lymphocytes

被引:0
|
作者
Watanabe, N
Kanegane, H
Kinuya, S
Shuke, N
Yokoyama, K
Kato, H
Tomizawa, G
Shimizu, M
Funada, H
Seto, H
机构
[1] Toyama Med & Pharmaceut Univ, Dept Radiol, Toyama 9300194, Japan
[2] Toyama Med & Pharmaceut Univ, Dept Pediat, Toyama, Japan
[3] Kanazawa Univ, Dept Nucl Med, Kanazawa, Ishikawa 920, Japan
[4] Asahikawa Med Univ, Dept Radiol, Asahikawa, Hokkaido, Japan
[5] Toyama Med & Pharmaceut Univ, Dept Clin Infect Dis, Toyama, Japan
关键词
micronucleus assay; thyroid cancer; radioiodine therapy; radiotoxicity; B lymphocytes;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We investigated cytologic radiation damage in thyroid cancer after I-131 therapy using micronucleus assay (MNA) of B lymphocytes exclusively, as opposed to our previous study in which MNA of all lymphocyte subsets was used. Methods: We studied 22 thyroid cancer patients treated with 3.7 GBq of I-131. Peripheral lymphocytes were harvested, and B lymphocytes were isolated by an immunomagnetic method and assayed for the frequency of micronuclei. Results: The frequency of micronuclei among B cells after I-131 therapy was significantly increased relative to that in untreated control subjects, and the I-131-induced increase in micronuclei frequency among B cells was significantly greater than that among all lymphocytes. Conclusion: Compared with the MNA of all lymphocytes, the MNA among specifically B cells may more sensitively detect cytologic radiation damage associated with I-131 therapy of thyroid cancer.
引用
收藏
页码:608 / 611
页数:4
相关论文
共 50 条
  • [21] Alternative Means of Estimating 131I Maximum Permissible Activity to Treat Thyroid Cancer
    Nichols, Kenneth J.
    Robeson, William
    Yoshida-Hay, Miyuki
    Zanzonico, Pat B.
    Leveque, Fritzgerald
    Bhargava, Kuldeep K.
    Tronco, Gene G.
    Palestro, Christopher J.
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (10) : 1588 - 1595
  • [22] Advances in Antioxidant Applications for Combating 131I Side Effects in Thyroid Cancer Treatment
    Yang, Li
    Ma, Jiahui
    Lei, Pengyu
    Yi, Jia
    Ma, Yilei
    Huang, Zhongke
    Wang, Tingjue
    Ping, Haiyan
    Ruan, Danping
    Sun, Da
    Pan, Hongying
    TOXICS, 2023, 11 (06)
  • [23] The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I
    Verburg, F. A.
    Verkooijen, R. B. T.
    Stokkel, M. P. M.
    van Isselt, J. W.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2009, 48 (04): : 138 - 142
  • [24] Chromosome aberrations after high-dose 131I and 99mTc-MIBI administration using a micronucleus assay
    Asli, Isa Neshandar
    Mosaffa, Nariman
    Mogharrabi, Mehdi
    Hooman, Aref
    Tabei, Faraj
    Javadi, Hamid
    Shafei, Babak
    Seyedabadi, Mohammad
    Assadi, Majid
    NUCLEAR MEDICINE COMMUNICATIONS, 2010, 31 (04) : 307 - 310
  • [25] Investigation of the effect of 131I on blood parameters for thyroid cancer treatment
    Khandaker, Mayeen Uddin
    Hassanpour, Mehdi
    Khezripour, Saeedeh
    Rezaei, Mohammad Reza
    Bazghandi, Atefeh
    Hassanpour, Marzieh
    Faruque, Mohammad Rashed Iqbal
    Bradley, D. A.
    RADIATION PHYSICS AND CHEMISTRY, 2023, 208
  • [26] Elevated 131I Activity in Adrenal Cyst in a Patient With Thyroid Cancer
    Liu, Wei
    Yang, Xiao
    Gong, Weidong
    Wang, Jianqiang
    Fan, Xueyuan
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (10) : 959 - 961
  • [27] Variable 131I Activity in Renal Stone in a Patient With Thyroid Cancer
    Liu, Shihong
    Chen, Li
    Zhang, Deping
    Cao, Chengjian
    Shao, Fuqiang
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (04) : 332 - 334
  • [28] Importance of Postoperative Stimulated Thyroglobulin Level at the Time of 131I Ablation Therapy for Differentiated Thyroid Cancer
    Hasbek, Zekiye
    Turgut, Bulent
    Kilicli, Fatih
    Altuntas, Emine Elif
    Yucel, Birsen
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (06) : 2523 - 2527
  • [29] Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications
    Szumowski, Piotr
    Abdelrazek, Saeid
    Iwanicka, Dorota
    Mojsak, Malgorzata
    Sykala, Monika
    Zukowski, Lukasz
    Siewko, Katarzyna
    Adamska, Agnieszka
    Maliszewska, Katarzyna
    Poplawska-Kita, Anna
    Szelachowska, Malgorzata
    Kretowski, Adam
    Mysliwiec, Janusz
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [30] Ablative treatment of thyroid cancer with high doses of 131I without pre-therapy scanning
    Rosário, PWS
    Barroso, AL
    Rezende, LL
    Padrao, EL
    Borges, MAR
    Fagundes, TA
    Purisch, S
    NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (02) : 129 - 132